Navigation Links
Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development
Date:6/17/2009

Collaboration will focus on the development of TMC207 and the discovery of new drugs to treat tuberculosis

SEATTLE, June 17 /PRNewswire/ -- A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Tibotec Inc., (Tibotec), a global pharmaceutical company, has been announced today at the Pacific Health Summit in response to the urgent need to accelerate the discovery and development of new drugs to fight tuberculosis (TB).

The two organizations will share their expertise and resources in the development of TMC207, which could become the first TB drug with a new mechanism of action in 40 years. The interim data from an ongoing Phase II study of TMC207 were recently published in the New England Journal of Medicine. In the placebo-controlled study of 47 patients with multidrug-resistant TB (MDR-TB), it was found that 48 percent of patients receiving TMC207 in combination with standard treatment converted to negative sputum culture after eight weeks compared with 9 percent of those who received placebo and standard treatment.

The collaboration will maximize the expertise and resources from both the public and private sectors with the intent to improve the treatment of one of the world's oldest and most deadly diseases. Increased efforts and resources to develop new and improved TB drugs are sorely needed. Among infectious diseases, tuberculosis is the second most common cause of adult deaths worldwide. The World Health Organization (WHO) estimates approximately one-third of the world's population is infected with Mycobacterium tuberculosis (M.tb), the bacillus that causes TB, and the disease is responsible for nearly 5,000 deaths per day, worldwide. MDR-TB, which is characterized by resistance to at least two of the most powerful medicines in today's standard, four-drug regimen for drug-susce
'/>"/>

SOURCE Tibotec Inc.; TB Alliance
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Unique role for blood formation gene identified
2. New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nations Chiropractic Care: Focus on the Patients
3. Blue Cross and Blue Shield Association Nationally Recognized by BusinessWeek and AARP for Creating a Unique Workplace Environment for New and Mature Employees
4. Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors
5. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
6. Graduates of Unique New Labor/Management Healthcare Workforce Training Program Honored Today in Oakland
7. Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
8. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
9. The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa
10. Franco e Rizzi Offers Low-Cost Weight Loss Surgery (WLS) With Unique Price Guarantee
11. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... the secrets to better treating the pernicious disorders of ... a paper from American University,s Center for Behavioral Neuroscience. ... obesity with therapies aimed at areas of the brain ... on the hippocampus could play a role in reducing ... therapies and preventive measures often fall short. This is ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) --,Jealousy may not be the ... can get downright possessive when it comes to the ... affection toward what was actually a stuffed dog, the ... pushing the stuffed dog aside, report researchers from the ... streak only surfaced when owners were attending to the ...
(Date:7/23/2014)... research on human cancer genes have been focused on ... to be translated in the form of amino acids ... a regulatory region or activator which controls the expression ... little was known of the role exerted such DNA ... today in Nature in collaboration with the ...
(Date:7/23/2014)... County, NJ (PRWEB) July 23, 2014 ... is the first hospital in New Jersey to receive ... most advanced robotics platform in the da Vinci series. ... and a profound step forward in innovation. The intuitive ... used across a wide spectrum of minimally invasive and ...
(Date:7/23/2014)... Vancouver, BC (PRWEB) July 23, 2014 ... has recently announced the launch of its custom orthotics ... correcting and eliminating foot abnormalities in order to restore ... the joints and cause less fatigue and pain. In ... and reduced pressure in the foot, resulting in relief ...
Breaking Medicine News(10 mins):Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Dogs Can Get Jealous, Too 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:Custom Orthotics at Burnaby PhysioCare Now Correct Foot Abnormalities 2
... risk of obesity later in life, research suggests , ... during pregnancy reduces an infant,s birth weight, which may ... researchers say. , In a new study, 84 first-time ... groups, with those in the exercise group participating in ...
... ... Laboratory Notebook) to be fully supported on the revolutionary Apple iPad. , ... (PRWEB) April 5, 2010 -- Amphora Research ... supported on the revolutionary Apple iPad., , ,"Science often happens in places where using a ...
... ... today. This newly launched initiative from MedPage Today, the online daily breaking medical news ... and critical thinkers while preserving their editorial independence. , ... Little Falls, New Jersey (PRWEB) April 5, 2010 ...
... finds relationships often founder after failed pregnancy, , MONDAY, April ... when she miscarried at 14 weeks. That she was already ... understand was that having my other children and realizing how ... who lives in Highland Ranch, Colo. , At first, her ...
... ... Day on April 7th, Swanson Health Products will donate five percent of the day,s sales ... ... Health Products plans to donate five percent of sales from Wednesday, April 7th, to Vitamin ...
... ... Expanded Its Free Webinars to Cover New Obama Health Reform ... Insurance Reimbursement Checks Directly with Valid Assignment and Nondiscrimination Protections ... and Individual Health Plan to Accept Patient Assignment to Send ...
Cached Medicine News:Health News:Expectant Mom's Exercise Keeps Newborn's Birth Weight Down 2Health News:Amphora's PatentSafe Electronic Laboratory Notebook Fully Supported on the Apple iPad 2Health News:MedPage Today Launches New Related SitesTM Initiative with KevinMD.com as First Collaborator 2Health News:MedPage Today Launches New Related SitesTM Initiative with KevinMD.com as First Collaborator 3Health News:For Many Couples, Toll of Miscarriage Lingers 2Health News:For Many Couples, Toll of Miscarriage Lingers 3Health News:For Many Couples, Toll of Miscarriage Lingers 4Health News:Swanson Health Products to Make Donation for Haiti Relief Efforts 2Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 2Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 3Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 4Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 5
(Date:7/23/2014)... LONDON , July 23, 2014  Lightlake ... developing addiction treatments based on its expertise in ... an investigational new drug application ("IND") with respect ... Lightlake also announced today that it has received ... Drug Abuse ("NIDA"), part of the National Institutes ...
(Date:7/23/2014)... , July 23, 2014  Silk Road ... the transcarotid treatment of intra- and extra-cranial cerebrovascular ... P. Wallace to the position of Chief ... lead the company,s Research and Development efforts across ... Prior to joining Silk Road ...
(Date:7/23/2014)... , July 23, 2014  ACON Equity Partners III, ... Investments, L.L.C. ("ACON") announced it has completed the purchase ... from Audax Group and Parthenon Capital Partners. IWP is ... billion Workers, Compensation, Automobile Personal Injury Protection and Personal ... . As part of this ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3ACON Investments Acquires Injured Workers Pharmacy 2ACON Investments Acquires Injured Workers Pharmacy 3
... Therapeutics, Inc. (Nasdaq: ECTE ), a company ... wireless, transdermal continuous glucose monitoring system and its Prelude® ... results for the year ended December 31, 2011.  Echo,s ... website at www.echotx.com . 2011 ...
...   Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... of senior vice president and chief commercial officer. Mr. Palekar ... activities. "Rohan has an outstanding track record of ... president and CEO of Avanir. "I am delighted that we ...
Cached Medicine Technology:Echo Therapeutics, Inc. Announces 2011 Financial Results 2Echo Therapeutics, Inc. Announces 2011 Financial Results 3Echo Therapeutics, Inc. Announces 2011 Financial Results 4Echo Therapeutics, Inc. Announces 2011 Financial Results 5Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 2Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 3
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: